Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pelareorep - Oncolytics Biotech

X
Drug Profile

Pelareorep - Oncolytics Biotech

Alternative Names: AN-1004; PO-BB0209; REOLYSIN; Reosyn; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus; Wild-type reovirus - Oncolytics Biotech

Latest Information Update: 02 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncolytics Biotech
  • Developer Adlai Nortye; Canadian Cancer Society Research Institute; Mayo Clinic; National Cancer Institute (USA); Oncolytics Biotech; PrECOG; Roche; University of Leeds; University of Southern California
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Peritoneal cancer; Ovarian cancer; Gastric cancer; Pancreatic cancer; Fallopian tube cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer; Head and neck cancer
  • Phase II Brain cancer; Colorectal cancer; Fallopian tube cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma
  • Phase I/II Anal cancer; Glioma; Multiple myeloma
  • Preclinical Acute myeloid leukaemia
  • No development reported Glioblastoma; Liver cancer; Solid tumours

Most Recent Events

  • 23 Dec 2024 Oncolytics Biotech plans a registrational study in Pancreatic cancer (First line therapy, Combination therapy) in 2025
  • 23 Dec 2024 Oncolytics Biotech plans a registration-enabling trial for HR+/HER2- Breast cancer (Metastatic disease, Combination therapy) in H2 2025
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top